ClinicalTrials.gg
CompletedNCT06933043Updated Mar 6, 2026

A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.

A Phase 1 interventional study of NAV-240 and Placebo in Healthy Volunteers, sponsored by Navigator Medicines, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Navigator Medicines, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to assess initial safety/tolerability of multiple doses of drug NAV-240. It will also learn about the profile and immunogenicity of drug NAV-240. The main question it aims to answer is:

  • What medical problems do participants have when taking multiple doses of drug NAV-240? Researchers will compare drug NAV-240 to a placebo (a look-alike substance that contains no drug) to see if any medical problems participants have differ between those taking drug NAV-240 and those taking placebo.
Read the detailed description

This randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study will evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and immunogenicity of NAV-240.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • health volunteer
03

In context

Lead sponsor

Navigator Medicines, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Selected Inclusion Criteria:

  • Male and female participants 18 - 65 years of age
  • Medically healthy, in the opinion of the Investigator, with no findings on medical history, physical examination, vital signs, or (ECGs) at Screening, and/or before administration of the initial dose of study drug.
  • Participants must have clinical laboratory values within normal ranges of (ULN) as specified by the testing laboratory, unless deemed not clinically significant (NCS) by the Investigator.
  • (BMI) 18 to ≤35 kg/m2 at Screening.
  • Female participants of must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1.
  • Female participants of childbearing potential who are sexually active with a male partner of must agree to the use highly effective method of established from at least 28 days prior to screening until at least 90 days after study drug dosing.
  • Male participants with female partners who are of reproductive potential must agree to the use of a male condom PLUS a highly effective, method of contraception for the duration of the study, and for at least 90 days after study drug dosing. Male healthy participants also must agree to refrain from sperm donation during the study and for at least 90 days after study drug dosing. Note: Males who are surgically sterile (i.e., documented successful vasectomy) will also be required to use a male condom. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.
  • Participants must provide signed prior to study entry and have the ability and willingness to attend and comply with the necessary visits at the study site. They must also receive a copy of the fully executed informed consent document.

Selected Exclusion Criteria:

  • A relevant history of severe respiratory disease that required treatment and/or follow up under the direction of a physician.
  • Any neurological, psychiatric, vascular, or system disorder that could also affect the evaluation of disease activity assessments.
  • Any other significant acute or chronic medical illness that, in the opinion of the Investigator, would impact the participant's ability to complete all study requirements or that might impact the assessment of study data, or the participant has had a clinically significant illness within 30 days prior to study drug dosing per the Investigator's discretion.
  • History of alcoholism or drug abuse within the prior 2 years.
  • Acute COVID infection (within three months of Screening) or long COVID.
  • A history and/or current presence of a clinically significant atopic allergy, , or allergic reactions.
  • Known or suspected clinically relevant drug hypersensitivity to any components of the test and reference product formulation or comparable drugs.
  • A history of any infection requiring hospitalization, IV or oral antibiotics, or as otherwise judged clinically significant, within the 3 months prior to Screening, or an opportunistic infection within the past 12 months, or ongoing infection including chronic viral disease.
  • A positive test result for drugs of abuse, cotinine, or alcohol at Screening and on Day -1.
  • Active tuberculosis (TB) or a history of TB, or a positive TB blood test at Screening.
  • Systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg confirmed by repeat.
  • Abnormalities on 12-lead echocardiogram (ECG) prior to study drug dosing, confirmed by repeat.
  • All prescription and over-the-counter medications (including vitamins and dietary or herbal supplements), except for contraceptives and acetaminophen, as needed, are prohibited within 7 days prior to the first study drug administration and throughout the treatment period of the study.
  • Received vaccines (whether live, attenuated, or killed/inactivated) within 4 weeks prior to Day 1 or is planning to receive any vaccine over the course of the study. Note, influenza vaccines (inactivated) will be allowed during the study.
  • Received anti-TNF therapy in the past, confirmed by participant and Investigator.
  • Receipt of any investigational drug within 30 days prior to Screening or 5 half-lives, whichever is longer.
  • Females who are pregnant or breastfeeding.
  • Active cigarette smoker or has regularly used nicotine or nicotine-containing products
  • Any reason which, in the opinion of the Investigator, would prevent the healthy participant from participating in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    NAV-240

    Participants will be enrolled in 1 of 3 multiple ascending dose cohorts. Six participants in each cohort will receive NAV-240.

    Drug: NAV-240

  • Placebo comparator
    Placebo to match NAV-240

    In each multiple ascending dose cohort, 2 participants will receive matching placebo.

    Drug: Placebo

Interventions

  • Three doses of intravenous (IV) low dose, medium dose or high dose NAV-240 will be administered to participants.

  • DrugPlacebo

    Three doses of matching placebo will be administered to participants.

06

What researchers measure

Primary outcomes

  1. Presence and severity of any treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs)

    Incidence, nature, and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Through 6 weeks after last dose of study drug.

Secondary outcomes

  1. Pharmacokinetics parameter - maximum observed concentration (Cmax)

    Maximum observed concentration of the study drug in serum will be analyzed for all participants

    Time frame: Through to Day 99.

  2. Pharmacokinetics parameter - Time for maximum observed Concentration (Tmax)

    Serum PK Tmax will be analyzed for all participants

    Time frame: Through to Day 99.

  3. Pharmacokinetics parameter - Area under the curve (AUC)

    Area under the curve of the study drug in serum will be analyzed for all participants.

    Time frame: Through to Day 99.

  4. Pharmacokinetics parameter - Volume of distribution (Vz)

    Volume of distribution of the study drug in serum will be analyzed for all participants.

    Time frame: Through to Day 99.

  5. Immunogenicity of study drug - Anti-Drug Antibodies (ADAs)

    Serum Anti-Drug Antibodies will be analyzed for all participants

    Time frame: Through to Day 99.

07

Study locations

1 site
  • Nucleus Network
    Brisbane, Queensland 4006, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Nov 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 17, 2025
StartActual
May 20, 2025
Primary completionActual
Nov 20, 2025
CompletionActual
Nov 20, 2025
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06933043
Lead sponsor
Navigator Medicines, Inc.
Collaborators
Southern Star Research
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
May 20, 2025
Primary completion
Nov 20, 2025
Completion
Nov 20, 2025
Last update
Mar 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NAV-240

Start the discussion